Research Reports

Summary

Xilio Therapeutics, Inc. appointed Cheryl R. Blanchard, Ph.D. as a Class III director effective April 15, 2026, to serve until the 2027 annual meeting, and she assumed roles as chair of the Compensation Committee and member of the Audit Committee, succeeding Christina Rossi who resigned effective the same date.

Key takeaways

Dr. Cheryl R. Blanchard was elected as a Class III director effective April 15, 2026, with term expiring at the 2027 annual meeting.

Dr. Blanchard was appointed chair of the Compensation Committee and member of the Audit Committee, replacing prior committee assignments held by departing director Christina Rossi.

Dr. Blanchard will receive $40,000 annual cash fee for Board service, plus $12,000 for Compensation Committee chair and $7,500 for Audit Committee membership.

She received an initial stock option grant for 10,000 shares, vesting one-third annually over three years, and will be eligible for annual 5,000-share option grants after six months of service.

Christina Rossi resigned from the Board and all committees effective April 15, 2026, with no disagreement cited.

Full analysis

The appointment of Dr. Cheryl R. Blanchard as a Class III director and her assumption of leadership roles on two key Board committees—Compensation (as chair) and Audit—represents a strategic reinforcement of governance oversight at Xilio Therapeutics. Her background, though not detailed in the filing, is implicitly valued given the scope of responsibilities assigned. The compensation structure aligns with the newly amended and restated Non-Employee Director Compensation Policy effective April 15, 2026, which standardizes cash retainers and equity awards across non-employee directors. Notably, Dr. Blanchard’s initial and annual equity grants follow the same vesting mechanics and share amounts specified in the policy, reinforcing consistency and transparency in director pay. Her succession of Christina Rossi—who stepped down without controversy—ensures continuity in committee operations and avoids governance gaps ahead of the 2027 annual meeting. While this is a routine board refresh, the dual committee leadership assignment signals heightened emphasis on compensation design and financial oversight during a critical phase for the company, likely tied to ongoing clinical development and capital allocation decisions.